NASDAQ$ABOS
Acumen Pharmaceuticals Inc · Q2 2022 earnings
Q2 2022 earnings · · Investor relations
Briefing
Acumen Pharmaceuticals reported financial results for the second quarter of 2022 and provided a business update.
Acumen Pharmaceuticals reported $209.9 million in cash, cash equivalents and marketable securities as of June 30, 2022. R&D expenses were $7.3 million, and G&A expenses were $3.1 million for the three-month period ended June 30, 2022. The net loss was $10.2 million for the three-month period ended June 30, 2022.
- Topline results expected in the first half of 2023 from INTERCEPT-AD, a Phase 1 clinical trial of ACU193 in patients with early Alzheimer’s disease (AD).
- Key methods and assay model developed to potentially standardize the study of soluble amyloid-beta oligomers (AßOs) presented in a poster at the recent Alzheimer’s Association International Conference (AAIC).
- $209.9 million in cash, cash equivalents and marketable securities as of June 30, 2022, which is expected to provide cash runway through 2025.
- Company to host conference call and webcast today at 4:30 pm ET
Headline financials
Revenue & EPS history
Acumen · Revenue · Quarterly
$16K
Forward guidance
Acumen anticipates initiating a Phase 2/3 trial for ACU193 following completion of INTERCEPT-AD, if successful, and subsequent consultation and feedback from the FDA.
Tailwinds
- INTERCEPT-AD enrollment remains ongoing.
- Patient screening and enrollment is continuing for INTERCEPT-AD.
- Acumen anticipates topline data from this trial in the first half of 2023.
- Methodology was recently presented in a poster at the 2022 Alzheimer’s Association International Conference.
- Acumen continues to expand its team with new appointments.
Headwinds
- Dr. Jeffrey Sevigny has departed from the Board effective August 12, 2022.
- Decrease in cash related to funding ongoing operations.
- Increase in research and development expenses was due to increased costs related to our ongoing clinical trial.
- Increase in general and administrative expenses was primarily due to increased costs related to personnel, insurance, legal, marketing and recruiting expenses.
- Losses from operations were $10.4 million for the three-month period ended June 30, 2022.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 17 quarterly earnings reports · overlaid with Q2 2022
+0.6%
Avg return
Earnings day
-3.3%
Avg return
5 days after
-6.4%
Avg return
30 days after
42%
8 / 19 earnings
Positive
+35.9%
Q1 2023
Best reaction
-21.4%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -2.3% | -9.8% | — | |
| Q1 2026 | -3.5% | -11.7% | -7.8% | |
| Q3 2025 | -1.5% | -19.8% | +8.6% | |
| Q1 2025 | +0.0% | +1.9% | +8.6% | |
| Q4 2024 | +6.0% | -7.3% | -6.9% | |
| Q3 2024 | -21.4% | -25.5% | -35.7% | |
| Q2 2024 | -1.6% | +0.4% | -4.3% | |
| Q1 2024 | +13.1% | +8.6% | -21.4% | |
| Q4 2023 | -3.5% | +8.0% | -20.6% | |
| Q3 2023 | +12.1% | +20.0% | +53.2% | |
| Q2 2023 | -3.1% | +2.0% | -19.9% | |
| Q1 2023 | +35.9% | +15.5% | +0.4% | |
| Q4 2022 | +2.3% | +3.6% | -4.1% | |
| Q3 2022 | -5.1% | -10.6% | -15.3% | |
| Q2 2022 | +4.6% | -11.5% | +9.4% | |
| Q1 2022 | +9.6% | +4.5% | +7.8% | |
| Q4 2021 | -14.8% | -22.0% | -22.2% | |
| Q3 2021 | -17.1% | -23.9% | -46.7% | |
| Q2 2021 | +1.6% | +13.9% | +1.1% | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro